Promising combo for eye cancer stalls after only 3 patients enrolled

NCT ID NCT03712904

Terminated Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II trial tested a combination of precise radiation therapy followed by injections of aflibercept (Eylea) in people with uveal melanoma, a rare eye cancer. The goal was to see if this approach could control the tumor while reducing side effects like swelling or damage to the retina. However, the study was terminated early after enrolling only 3 participants, so we have very little data to draw conclusions from.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aflibercept (Eylea) and stereotactic body radiation therapy
What this could lead to: If successful, this combination could offer a new way to control uveal melanoma while reducing damage to healthy eye tissue.
What could go wrong: This was a very small, early-phase trial that was terminated early with only 3 participants, so results are extremely limited and may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.